U.S. Markets closed

Ionis Pharmaceuticals’ Valuations on September 28

Mike Benson
Ionis Pharmaceuticals’ Valuations on September 28

Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.